全文获取类型
收费全文 | 8130篇 |
免费 | 577篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 48篇 |
儿科学 | 292篇 |
妇产科学 | 177篇 |
基础医学 | 1356篇 |
口腔科学 | 105篇 |
临床医学 | 818篇 |
内科学 | 1620篇 |
皮肤病学 | 194篇 |
神经病学 | 760篇 |
特种医学 | 192篇 |
外国民族医学 | 1篇 |
外科学 | 931篇 |
综合类 | 107篇 |
一般理论 | 2篇 |
预防医学 | 774篇 |
眼科学 | 130篇 |
药学 | 480篇 |
中国医学 | 36篇 |
肿瘤学 | 707篇 |
出版年
2023年 | 50篇 |
2022年 | 81篇 |
2021年 | 165篇 |
2020年 | 109篇 |
2019年 | 163篇 |
2018年 | 178篇 |
2017年 | 145篇 |
2016年 | 167篇 |
2015年 | 201篇 |
2014年 | 237篇 |
2013年 | 330篇 |
2012年 | 558篇 |
2011年 | 563篇 |
2010年 | 302篇 |
2009年 | 312篇 |
2008年 | 521篇 |
2007年 | 524篇 |
2006年 | 590篇 |
2005年 | 506篇 |
2004年 | 492篇 |
2003年 | 457篇 |
2002年 | 423篇 |
2001年 | 143篇 |
2000年 | 116篇 |
1999年 | 96篇 |
1998年 | 109篇 |
1997年 | 93篇 |
1996年 | 79篇 |
1995年 | 89篇 |
1994年 | 51篇 |
1993年 | 61篇 |
1992年 | 47篇 |
1991年 | 50篇 |
1990年 | 50篇 |
1989年 | 38篇 |
1988年 | 37篇 |
1987年 | 34篇 |
1986年 | 47篇 |
1985年 | 50篇 |
1984年 | 33篇 |
1983年 | 41篇 |
1982年 | 29篇 |
1981年 | 23篇 |
1980年 | 30篇 |
1979年 | 27篇 |
1978年 | 23篇 |
1976年 | 15篇 |
1975年 | 15篇 |
1974年 | 23篇 |
1973年 | 19篇 |
排序方式: 共有8730条查询结果,搜索用时 46 毫秒
1.
Cromb Amandine Le Loarer Franois Sitbon Maxime Italiano Antoine Stoeckle Eberhard Buy Xavier Kind Michle 《European radiology》2020,30(5):2413-2424
European Radiology - The strongest adverse prognostic factor in myxoid/round cell liposarcomas (MRC-LPS) is the presence of a round cell component above 5% within the tumor bulk. Its identification... 相似文献
2.
3.
4.
5.
6.
Dominique Trudel Luminita-Mihaela Avarvarei Michèle Orain Stéphane Turcotte Marie Plante Jean Grégoire Reinhild Kappelhoff David P. Labbé Dimcho Bachvarov Bernard Têtu Christopher M. Overall Isabelle Bairati 《Pathology, research and practice》2019,215(6):152369
Ovarian carcinoma is one of the most lethal malignancies, but only very few prognostic biomarkers are known. The degradome, comprising proteases, protease non-proteolytic homologues and inhibitors, have been involved in the prognosis of many cancer types, including ovarian carcinoma. The prognostic significance of the whole degradome family has not been specifically studied in high-grade serous ovarian cancer. A targeted DNA microarray known as the CLIP-CHIP microarray was used to identify potential prognostic factors in ten high-grade serous ovarian cancer women who had early recurrence (<1.6 years) or late/no recurrence after first line surgery and chemotherapy. In women with early recurrence, we identified seven upregulated genes (TMPRSS4, MASP1/3, SPC18, PSMB1, IGFBP2, CFI – encoding Complement Factor I – and MMP9) and one down-regulated gene (ADAM-10). Using immunohistochemistry, we evaluated the prognostic effect of these 8 candidate genes in an independent cohort of 112 high-grade serous ovarian cancer women. Outcomes were progression, defined according to CA-125 criteria, and death. Multivariate Cox proportional hazard regression models were done to estimate the associations between each protein and each outcome. High ADAM-10 expression (intensity of 2–3) was associated with a lower risk of progression (adjusted hazard ratio (HR): 0.51; 95% confidence interval (CI): 0.29-0.87). High complement factor I expression (intensity 2–3) was associated with a higher risk of progression (adjusted HR: 2.30, 95% CI: 1.17–4.53) and death (adjusted HR: 3.42; 95% CI: 1.72–6.79). Overall, we identified the prognostic value of two proteases, ADAM-10 and complement factor I, for high-grade serous ovarian cancer which could have clinical significance. 相似文献
7.
Background
In meningitis, the cerebrospinal fluid contains high levels of innate immune molecules (e.g. complement) which are essential to ward off the infectious challenge and to promote the infiltration of phagocytes (neutrophils, monocytes). However, epithelial cells of either the ependymal layer, one of the established niche for adult neural stem cells, or of the choroid plexus may be extremely vulnerable to bystander attack by cytotoxic and cytolytic complement components. 相似文献8.
9.
10.
Anita Rachlis Jonathan Angel Marianne Harris Richard Lalonde Fiona Smaill Cecile Tremblay Chris Tsoukas Sharon Walmsley 《The Canadian Journal of Infectious Diseases & Medical Microbiology》2006,17(3):155-163
BACKGROUND AND OBJECTIVES: An eight-member group consisting of Canadian infectious disease and immunology specialists and a family physician with significant experience in HIV management was convened to update existing recommendations, specifically intended for use by Canadian HIV-treating physicians, on the appropriate use of enfuvirtide in HIV/AIDS patients with resistance to other antiretroviral drugs. METHODS: Evidence from the literature and expert opinions of the group members formed the basis of the guidelines. Comments on the draft guidelines were obtained from other physicians across Canada with HIV expertise. The final guidelines represent the group's consensus agreement. RESULTS AND CONCLUSIONS: The recommendations were developed to guide physicians in optimal practices in patient selection for enfuvirtide treatment and subsequent patient management. The issues considered include positive predictors of response to enfuvirtide, stage of disease, optimization of the background regimen, early indicators of enfuvirtide response, and patient education and support. 相似文献